Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA-Cognition Study.
Lazar R, Howard G, Brewer M, Cassarly C, Pauls Q, Kemp S, Tirschwell D, Sheth K, Wintermark M, Kamel H, Longstreth W, Elkind M, Broderick J, Lansberg M. Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA-Cognition Study. Journal Of The American Heart Association 2025, 14: e042147. PMID: 40847528, DOI: 10.1161/jaha.125.042147.Peer-Reviewed Original ResearchConceptsCognitive declineCognitive testsBaseline dementiaStandardized cognitive testsStroke Prevention StudyPrevention StudyCognitive trajectoriesCognitive AssessmentIndividual test scoresMixed-effects modelsAspirin armCognitive examPrimary analysisAtrial cardiopathyIndex strokeMean ageScoresFollow-upBaseline characteristicsStrokeTest scoresAnnual changesArmCryptogenic strokeApixaban armBenzodiazepine Initiation Effect on Mortality Among Medicare Beneficiaries Post‐Acute Ischemic Stroke
Sankaranarayanan M, Donahue M, Sun S, Brooks J, Schwamm L, Newhouse J, Hsu J, Blacker D, Haneuse S, Moura L. Benzodiazepine Initiation Effect on Mortality Among Medicare Beneficiaries Post‐Acute Ischemic Stroke. Pharmacoepidemiology And Drug Safety 2025, 34: e70194. PMID: 40706600, DOI: 10.1002/pds.70194.Peer-Reviewed Original ResearchConceptsDays post-dischargeRisk differencePost-dischargeBaseline dementiaRisk of deathMedicare beneficiariesOlder adultsAcute ischemic strokeMortality riskSample of Medicare beneficiariesOlder stroke survivorsMortality risk differencesOlder Medicare beneficiariesPost-acute ischemic strokeHigh riskOlder age groupsHigher risk of deathIschemic strokeStroke survivorsBenzodiazepine initiationTrial emulationVulnerable patientsDementiaDay mortality riskPrimary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply